Immunotherapy and the role of imaging

Significant advances in the genetic and molecular characterization of cancer have led to the development of effective immunotherapies. These therapeutics help the host immune system recognize cancer as foreign, promote the immune system, and relieve the inhibition that allows growth and spread of tumors. Experience with various immunotherapies, particularly the immunomodulatory monoclonal antibody ipilimumab, has demonstrated that unique patterns of response may be encountered that cannot be adequately captured by traditional response criteria, such as the World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), which have been used primarily with cytotoxic chemotherapies. In response to these observations, several novel response criteria have been developed to evaluate patients who receive immunotherapy, including immune‐related response criteria (irRC), immune‐related RECIST (irRECIST), and immune RECIST (iRECIST). These criteria are typically used in conjunction with RECIST version 1.1 in the clinical trial setting, because approval of new therapeutics by the US Food and Drug Administration relies on the responses derived from RECIST version 1.1. Finally, a wide variety of immune‐related adverse events may affect patients who receive immunotherapy, many of which can be identified on imaging studies such as computed tomography, magnetic resonance imaging, and 2‐deoxy‐2‐(fluorine‐18)fluoro‐D‐glucose–positron emission tomography/computed tomography. In this review, the authors present the role of imaging in the evaluation of patients treated with immunotherapy, including the background and application of irRC, irRECIST, and iRECIST; the imaging of immune‐related adverse events; and future directions in advanced imaging of immunotherapy. Cancer 2018;124:2906‐22. © 2018 American Cancer Society.

[1]  M. Suarez‐Almazor,et al.  Radiomics to predict immunotherapy-induced pneumonitis: proof of concept , 2018, Investigational New Drugs.

[2]  K. Flaherty,et al.  Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. , 2017, Cancer research.

[3]  G. McArthur,et al.  The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Sanjiv S Gambhir,et al.  Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging , 2017, The Journal of Nuclear Medicine.

[5]  Steven P Rowe,et al.  Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma , 2017, The Journal of Nuclear Medicine.

[6]  C. Rudin,et al.  Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[8]  S. Morbelli,et al.  Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? , 2017, World journal of radiology.

[9]  Michelle S. Miller,et al.  Rapid PD-L1 detection in tumors with PET using a highly specific peptide. , 2017, Biochemical and biophysical research communications.

[10]  B. Kolla,et al.  Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy– a report of two cases , 2016, Journal of Immunotherapy for Cancer.

[11]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[12]  J. Wolchok,et al.  Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Kefford,et al.  Residual FDG‐PET metabolic activity in metastatic melanoma patients with prolonged response to anti‐PD‐1 therapy , 2016, Pigment cell & melanoma research.

[14]  F. Hodi,et al.  PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course , 2016, Clinical Cancer Research.

[15]  Wojciech G. Lesniak,et al.  PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. , 2016, Bioconjugate chemistry.

[16]  D. Maintz,et al.  RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do , 2016, Current Radiology Reports.

[17]  K. Nikolaou,et al.  CT imaging of bone and bone marrow infiltration in malignant melanoma--Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. , 2016, European journal of radiology.

[18]  A. D. Van den Abbeele,et al.  Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT. , 2015, Clinical nuclear medicine.

[19]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[20]  F. Hodi,et al.  Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. , 2015, European journal of radiology.

[21]  Seongseok Yun,et al.  Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication , 2015, Case reports in oncological medicine.

[22]  A. D. Van den Abbeele,et al.  Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[23]  A. Hoos,et al.  1070PADAPTATION OF THE IMMUNE RELATED RESPONSE CRITERIA: IRRECIST. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Percy Ivy,et al.  Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. , 2014, European journal of cancer.

[25]  R. Sullivan,et al.  Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. , 2014, The Journal of clinical endocrinology and metabolism.

[26]  F. Hodi,et al.  Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? , 2014, Journal of Immunotherapy for Cancer.

[27]  W. Oh,et al.  Adverse event reporting in cancer clinical trial publications. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Chen,et al.  Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  V. Sondak,et al.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma , 2013, Nature Reviews Clinical Oncology.

[30]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[31]  A. Giobbie-Hurder,et al.  Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements , 2013, Clinical Cancer Research.

[32]  R. Dummer,et al.  Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab , 2013, Cancer.

[33]  A. Shinagare,et al.  Ipilimumab-associated colitis: CT findings. , 2013, AJR. American journal of roentgenology.

[34]  S. Tirumani,et al.  Ipilimumab associated hepatitis: imaging and clinicopathologic findings , 2013, Investigational New Drugs.

[35]  W. Oyen,et al.  In vivo imaging of therapy-induced anti-cancer immune responses in humans , 2012, Cellular and Molecular Life Sciences.

[36]  S. Rosenberg,et al.  CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[37]  C. Ng,et al.  Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. , 2011, AJR. American journal of roentgenology.

[38]  F. Hodi,et al.  Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. , 2011, AJR. American journal of roentgenology.

[39]  W. Oyen,et al.  Immunotherapy response evaluation with 18F-FDG-PET in patients with advanced stage renal cell carcinoma , 2011, World Journal of Urology.

[40]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[41]  Isabelle Boutron,et al.  Reporting of safety results in published reports of randomized controlled trials. , 2009, Archives of internal medicine.

[42]  R. Jacobs,et al.  Imaging Immune Response In vivo: Cytolytic Action of Genetically Altered T Cells Directed to Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[43]  N. Müller,et al.  Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.

[44]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[45]  J. Ioannidis,et al.  Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. , 2001, JAMA.

[46]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[47]  A. Ribas,et al.  An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. , 2016, Cancer research.

[48]  J. Wolchok,et al.  Ipilimumab: Developmental History, Clinical Considerations, and Future Perspectives , 2012 .

[49]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[50]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .